✦ LIBER ✦
High dose therapy may have no survival benefit over CHOEP primary chemotherapy for people with aggressive non-Hodgkin’s lymphoma: Abstracted from: Kaiser U, Uebelacker I, Birkmann U et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. Journal of Clinical Oncology 2002; 20: 4413–19
✍ Scribed by Axel Glasmacher
- Book ID
- 117487706
- Publisher
- Elsevier Science
- Year
- 2003
- Tongue
- English
- Weight
- 80 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0305-7372
No coin nor oath required. For personal study only.